Total Funding
70
77
Total FundingPost-IPO Equity raised
Growth Score
-14 pts
Heat Score
9 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
2342
Nyxoah is a medical device company focused on the development and commercialization of a hypoglossal nerve stimulation (HGNS) therapy.
- John Landry: CFO
- Maurits Boon: Chief Medical Officer
About the Company
Nyxoah is a health-technology company focused on the development and commercialization of innovative solutions and services to treat sleep disordered breathing conditions. Nyxoah's lead solution platform is based on the Genio® system, a validated, user-centered, next generation neurostimulation therapy for OSA, the world's most common
sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
